Scroll

enzalutamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
non-steroid antiandrogens	4628	915087-33-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: enzalutamide xtandi MDV3100 MDV-3100	Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors and inhibit androgen receptor nuclear translocation and interaction with DNA. A major metabolite, N‑desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model. Molecular weight: 464.44 Formula: C21H16F4N4O2S CLOGP: 3.35 LIPINSKI: 0 HAC: 6 HDO: 1 TPSA: 76.44 ALOGS: -5.53 ROTB: 4 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

enzalutamide
xtandi
MDV3100
MDV-3100

Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors and inhibit androgen receptor nuclear translocation and interaction with DNA. A major metabolite, N‑desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model.

Molecular weight: 464.44
Formula: C21H16F4N4O2S
CLOGP: 3.35
LIPINSKI: 0
HAC: 6
HDO: 1
TPSA: 76.44
ALOGS: -5.53
ROTB: 4

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.16	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 31, 2012	FDA	ASTELLAS
March 24, 2014	PMDA	Astellas Pharma Inc

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	43.69	37.00	15	229	82106	63406672

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	5422.83	16.65	2441	39039	85605	34829846
Prostatic specific antigen increased	3437.55	16.65	1087	40393	13593	34901858
Death	1833.43	16.65	2287	39193	395762	34519689
Fatigue	1092.58	16.65	1725	39755	368928	34546523
Underdose	913.06	16.65	405	41075	13375	34902076
Hot flush	758.66	16.65	388	41092	17678	34897773
Product size issue	690.99	16.65	163	41317	571	34914880
Metastases to bone	442.04	16.65	236	41244	11734	34903717
Decreased appetite	403.20	16.65	713	40767	165679	34749772
Dysphagia	391.55	16.65	424	41056	61957	34853494

Showing 1 to 10 of 153 entries

Previous1 2 3 4 5…16Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	3441.94	17.78	1446	29151	134544	79579247
Prostatic specific antigen increased	3429.47	17.78	795	29802	9591	79704200
Death	1450.30	17.78	1401	29196	565113	79148678
Fatigue	684.90	17.78	1248	29349	928479	78785312
Underdose	577.94	17.78	273	30324	32878	79680913
Product size issue	467.78	17.78	98	30499	700	79713091
Hot flush	461.50	17.78	278	30319	54599	79659192
Decreased appetite	374.66	17.78	552	30045	341866	79371925
Prostate cancer	336.35	17.78	190	30407	33078	79680713
Metastases to bone	318.02	17.78	165	30432	24262	79689529

Showing 1 to 10 of 119 entries

Previous1 2 3 4 5…12Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L02BB04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONE ANTAGONISTS AND RELATED AGENTS Anti-androgens
CHEBI has role	CHEBI:35497	antiandrogen
CHEBI has role	CHEBI:35610	antineoplastic agents
FDA EPC	N0000175560	Androgen Receptor Inhibitor
FDA MoA	N0000000243	Androgen Receptor Antagonists
FDA MoA	N0000185506	Cytochrome P450 3A4 Inducers
FDA MoA	N0000185507	Cytochrome P450 2C9 Inducers
FDA MoA	N0000185607	Cytochrome P450 2C19 Inducers

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Metastasis from malignant tumor of prostate	indication	314994000
Malignant tumor of prostate	indication	399068003	DOID:10283

Showing 1 to 2 of 2 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.88	acidic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
40MG	XTANDI	ASTELLAS	N203415	Aug. 31, 2012	RX	CAPSULE	ORAL	9126941	May 15, 2026	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
40MG	XTANDI	ASTELLAS	N203415	Aug. 31, 2012	RX	CAPSULE	ORAL	9126941	May 15, 2026	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
40MG	XTANDI	ASTELLAS	N203415	Aug. 31, 2012	RX	CAPSULE	ORAL	9126941	May 15, 2026	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
40MG	XTANDI	ASTELLAS	N213674	Aug. 4, 2020	RX	TABLET	ORAL	9126941	May 15, 2026	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
40MG	XTANDI	ASTELLAS	N213674	Aug. 4, 2020	RX	TABLET	ORAL	9126941	May 15, 2026	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
40MG	XTANDI	ASTELLAS	N203415	Aug. 31, 2012	RX	CAPSULE	ORAL	8183274	Aug. 24, 2026	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
40MG	XTANDI	ASTELLAS	N203415	Aug. 31, 2012	RX	CAPSULE	ORAL	8183274	Aug. 24, 2026	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
40MG	XTANDI	ASTELLAS	N203415	Aug. 31, 2012	RX	CAPSULE	ORAL	8183274	Aug. 24, 2026	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
40MG	XTANDI	ASTELLAS	N203415	Aug. 31, 2012	RX	CAPSULE	ORAL	8183274	Aug. 24, 2026	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
40MG	XTANDI	ASTELLAS	N213674	Aug. 4, 2020	RX	TABLET	ORAL	8183274	Aug. 24, 2026	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Showing 1 to 10 of 15 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN	ANTAGONIST	EC50	7.31	CHEMBL	CHEMBL
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	4.85	CHEMBL
Prostate-specific antigen	Surface antigen	P07288	KLK3_HUMAN		IC50	6.89	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		IC50	6.53	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
014630	NDDF
1307298	RXNORM
15951529	PUBCHEM_CID
192757	MMSL
28802	MMSL
4031716	VUID
4031716	VANDF
6812	IUPHAR_LIGAND_ID
703125003	SNOMEDCT_US
703684000	SNOMEDCT_US

Showing 1 to 10 of 20 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0125	CAPSULE	40 mg	ORAL	NDA	27 sections
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0125	CAPSULE	40 mg	ORAL	NDA	27 sections
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0125	CAPSULE	40 mg	ORAL	NDA	27 sections
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0125	CAPSULE	40 mg	ORAL	NDA	27 sections
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0625	TABLET	40 mg	ORAL	NDA	27 sections
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0625	TABLET	40 mg	ORAL	NDA	27 sections
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0625	TABLET	40 mg	ORAL	NDA	27 sections
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0625	TABLET	40 mg	ORAL	NDA	27 sections
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0725	TABLET	80 mg	ORAL	NDA	27 sections
Xtandi	HUMAN PRESCRIPTION DRUG LABEL	1	0469-0725	TABLET	80 mg	ORAL	NDA	27 sections

Showing 1 to 10 of 18 entries

Previous1 2Next